This is not about replacing Verilog. It’s about evolving the hardware development stack so engineers can operate at the level of intent, not just implementation.
NMD Pharma will also present an update on the ongoing SYNAPSE-MG Phase 2b clinical trial of ignaseclant in generalized myasthenia gravis Aarhus, Denmark, 10 March 2026 - NMD Pharma A/S, a clinical-sta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results